The makers of Zepbound, one of the most popular new brands of weight loss injectables on the market, are offering a massive price cut — if you're willing to purchase and dose your syringes out yourself.

Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug Zepbound. Before, the treatment had only been sold in injectable pens for a list price of $1,060 per month, but now, Lilly will also sell starter doses in vials that cost up to $549 a month, “expanding supply and access,” the company said.

Eli Lilly (LLY) cuts prices for weight loss drug Zepbound for self-paying customers but raises costs for patients in the assistance program. Read more here.

Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more. Consumers who pay for medications out of pocket without insurance must purchase these products through the LillyDirect program and must also have a valid prescription from their healthcare provider.

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but some patients see the company’s changes as putting the medication further out of reach.